BR0111911A - Preparados de ação prolongada de antibióticos de quinolona e processos para a sua preparação - Google Patents

Preparados de ação prolongada de antibióticos de quinolona e processos para a sua preparação

Info

Publication number
BR0111911A
BR0111911A BR0111911-7A BR0111911A BR0111911A BR 0111911 A BR0111911 A BR 0111911A BR 0111911 A BR0111911 A BR 0111911A BR 0111911 A BR0111911 A BR 0111911A
Authority
BR
Brazil
Prior art keywords
preparation
processes
acting
long
quinolone
Prior art date
Application number
BR0111911-7A
Other languages
English (en)
Other versions
BRPI0111911B8 (pt
BRPI0111911B1 (pt
Inventor
Venkata-Rangarao Kanikanti
Roland Rupp
Wolfgang Weber
Peter Deuringer
Jan-Olav Henck
Heino Stass
Takaaki Nishioka
Yoshifumi Katakawa
Chika Taniguchi
Hitoshi Ichihashi
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0111911A publication Critical patent/BR0111911A/pt
Publication of BRPI0111911B1 publication Critical patent/BRPI0111911B1/pt
Publication of BRPI0111911B8 publication Critical patent/BRPI0111911B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PREPARADOS DE AçãO PROLONGADA DE ANTIBIóTICOS DE QUINOLONA E PROCESSOS PARA A SUA PREPARAçãO". A presente invenção refere-se a um preparado aplicável por via oral contendo um antibiótico quinolono, que libera a substância ativa em ação prolongada. Uma forma de execução preferida refere-se a preparados, que contém como substância ativa a mistura de uma base quinolona livre e seu sal. Preferem-se particularmente misturas de cloridrato de ciprofloxacina e ciprofloxacina-betaína.
BRPI0111911A 2000-06-26 2001-06-13 preparado aplicável por via oral compreendendo ciprofloxacina BRPI0111911B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10031043A DE10031043A1 (de) 2000-06-26 2000-06-26 Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
PCT/EP2001/006695 WO2002000219A1 (de) 2000-06-26 2001-06-13 Retard-zubereitungen von chinolon-antibiotika und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
BR0111911A true BR0111911A (pt) 2003-05-13
BRPI0111911B1 BRPI0111911B1 (pt) 2015-08-25
BRPI0111911B8 BRPI0111911B8 (pt) 2021-05-25

Family

ID=7646816

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111911A BRPI0111911B8 (pt) 2000-06-26 2001-06-13 preparado aplicável por via oral compreendendo ciprofloxacina

Country Status (41)

Country Link
US (3) US7709022B2 (pt)
EP (1) EP1296685B1 (pt)
JP (1) JP4958373B2 (pt)
KR (1) KR100939617B1 (pt)
CN (1) CN1273138C (pt)
AR (1) AR029688A1 (pt)
AT (1) ATE355062T1 (pt)
AU (1) AU2001270573A1 (pt)
BG (1) BG65914B1 (pt)
BR (1) BRPI0111911B8 (pt)
CA (1) CA2414271C (pt)
CU (1) CU23264B7 (pt)
CY (1) CY1107574T1 (pt)
CZ (1) CZ301812B6 (pt)
DE (2) DE10031043A1 (pt)
DK (1) DK1296685T3 (pt)
DO (1) DOP2001000199A (pt)
EE (1) EE04992B1 (pt)
ES (1) ES2282270T3 (pt)
GT (1) GT200100126A (pt)
HK (1) HK1058479A1 (pt)
HN (1) HN2001000132A (pt)
HR (1) HRP20030050B1 (pt)
HU (1) HU229806B1 (pt)
IL (2) IL153333A0 (pt)
MA (1) MA25761A1 (pt)
MX (1) MXPA02012727A (pt)
MY (1) MY140994A (pt)
NO (1) NO325415B1 (pt)
NZ (1) NZ523352A (pt)
PE (1) PE20020207A1 (pt)
PL (1) PL203710B1 (pt)
PT (1) PT1296685E (pt)
RU (1) RU2332204C2 (pt)
SI (1) SI1296685T1 (pt)
SK (1) SK287384B6 (pt)
SV (1) SV2002000505A (pt)
TW (1) TWI279232B (pt)
UA (1) UA83616C2 (pt)
WO (1) WO2002000219A1 (pt)
ZA (1) ZA200210350B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US7491768B2 (en) * 2002-06-25 2009-02-17 Woong-Sig Moon Polymer resin formulation having anti-microbial or anti-coagulability and preparation method thereof
PT1594500E (pt) * 2003-02-10 2010-12-17 Bayer Schering Pharma Ag Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
CA2532714C (en) 2003-08-04 2010-11-16 Kyorin Pharmaceutical Co., Ltd. Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
WO2006060672A2 (en) * 2004-12-03 2006-06-08 Dr. Reddy's Laboratories Ltd. Modified release ciprofloxacin compositions
DK1868581T3 (da) * 2005-04-11 2012-07-09 Abbott Lab Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler
EP1880722B1 (en) * 2006-07-19 2010-03-17 Tabuk Pharmaceutical Manufacturing Co. Pharmaceutical compositions of ciprofloxacin
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
WO2009117130A2 (en) * 2008-03-21 2009-09-24 Mylan Pharmaceuticals, Inc. Extended release forumulation containing a wax
LT2395840T (lt) 2009-02-13 2020-07-10 Romark Laboratories, L.C. Nitazoksanido kontroliuojamo atpalaidavimo farmacinės kompozicijos
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
US11033624B2 (en) * 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
WO2015168642A1 (en) 2014-05-02 2015-11-05 Labib Mohamed E Drug-releasing device usable in mucosal body cavities
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
FR2100858B1 (pt) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3142854A1 (de) 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-piperazino-chinolin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4530928A (en) * 1982-01-13 1985-07-23 Merck & Co., Inc. Quinoline carboxylic acid complexes with guanidinium carbonate
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
IT1198386B (it) 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5286754A (en) * 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
GB2196252B (en) 1986-09-18 1990-10-17 London Pharmacy Innovation Gastric controlled-release dosage forms
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP2958731B2 (ja) * 1992-02-14 1999-10-06 日本特殊陶業株式会社 酸化アルミニウム基焼結体及びその製造方法
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
JP2686215B2 (ja) 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
CN1048628C (zh) 1995-07-06 2000-01-26 东北制药总厂 环丙沙星注射液的制备方法
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
IN186245B (pt) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
PT1017392E (pt) * 1997-09-25 2002-10-31 Bayer Ag Formulacao de medicamento com libertacao controlada do principio activo
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
CZ2001901A3 (cs) 1998-09-14 2001-08-15 Ranbaxy Laboratories Limited Farmaceutická kompozice představující systém řízeného dodávání léku pro orální podání, poskytující časovou a místní kontrolu
IL149421A0 (en) 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6780057B2 (en) * 2001-12-21 2004-08-24 Intel Corporation Coaxial dual pin sockets for high speed I/O applications

Also Published As

Publication number Publication date
HN2001000132A (es) 2001-09-11
MA25761A1 (fr) 2003-04-01
KR20030023883A (ko) 2003-03-20
CU23264B7 (es) 2008-03-14
JP2004504278A (ja) 2004-02-12
HUP0300953A3 (en) 2009-04-28
TWI279232B (en) 2007-04-21
ES2282270T3 (es) 2007-10-16
PE20020207A1 (es) 2002-04-27
CA2414271A1 (en) 2002-12-23
PL360632A1 (en) 2004-09-20
WO2002000219A1 (de) 2002-01-03
DE10031043A1 (de) 2002-02-14
EE04992B1 (et) 2008-04-15
HRP20030050A2 (en) 2004-06-30
SK287384B6 (sk) 2010-08-09
ATE355062T1 (de) 2006-03-15
HU229806B1 (en) 2014-07-28
JP4958373B2 (ja) 2012-06-20
MXPA02012727A (es) 2003-05-14
DOP2001000199A (es) 2002-05-15
CY1107574T1 (el) 2013-03-13
AR029688A1 (es) 2003-07-10
BRPI0111911B8 (pt) 2021-05-25
EP1296685A1 (de) 2003-04-02
EP1296685B1 (de) 2007-02-28
HK1058479A1 (en) 2004-05-21
NO20026160L (no) 2002-12-20
DE50112123D1 (de) 2007-04-12
HRP20030050B1 (en) 2011-07-31
CZ20024216A3 (cs) 2003-04-16
EE200200707A (et) 2004-08-16
CN1438889A (zh) 2003-08-27
US8187632B2 (en) 2012-05-29
CA2414271C (en) 2005-09-27
MY140994A (en) 2010-02-12
US7709022B2 (en) 2010-05-04
BG107372A (bg) 2003-09-30
KR100939617B1 (ko) 2010-02-01
SV2002000505A (es) 2002-12-02
IL153333A (en) 2010-05-31
NO20026160D0 (no) 2002-12-20
UA83616C2 (uk) 2008-08-11
CZ301812B6 (cs) 2010-06-30
BRPI0111911B1 (pt) 2015-08-25
IL153333A0 (en) 2003-07-06
CN1273138C (zh) 2006-09-06
RU2332204C2 (ru) 2008-08-27
PL203710B1 (pl) 2009-11-30
ZA200210350B (en) 2004-02-10
NZ523352A (en) 2004-08-27
NO325415B1 (no) 2008-04-21
PT1296685E (pt) 2007-05-31
US20070065509A1 (en) 2007-03-22
US20070237824A1 (en) 2007-10-11
SK18212002A3 (sk) 2003-04-01
BG65914B1 (bg) 2010-05-31
DK1296685T3 (da) 2007-05-07
US20040024018A1 (en) 2004-02-05
SI1296685T1 (sl) 2007-06-30
GT200100126A (es) 2002-01-31
HUP0300953A2 (hu) 2003-08-28
US7780986B2 (en) 2010-08-24
AU2001270573A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
BR0111911A (pt) Preparados de ação prolongada de antibióticos de quinolona e processos para a sua preparação
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CU23367A3 (es) Formulación de moxifloxacino con sal común
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
PT1412384E (pt) Formulação estável de glp-1 modificado
HUP0101237A1 (hu) Elnyújtott kioldódású gyógyszerkészítmények
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR9808290A (pt) Composto, composição farmacêutica, processo de tratar infecções bacterianas em seres humanos e animais, uso de um composto, e, processo para sua preparação
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
NO20025358L (no) Ortosubstituerte antranilsyreamider og deres anvendelse som legemidler
AR032293A1 (es) Estuche farmaceutico
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BR9913135A (pt) Formulação oral
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
SE0102440D0 (sv) New compound

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE AG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.